Imugene Share Price and Company Fundamentals



Price
$0.3
Change
0.000 (0.000%)
52 week
0.045 - 0.495

Last traded: Today at 1:03 AM

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

Key Metrics

PE ratio

-

PB ratio

23.08

Dividend yield

Beta

2.16

Market cap

$1.5B

Enterprise value

$1.34B

Company profile

Primary activities.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.imugene.com
Mailing address37 Bligh Street Suite 1006 Level 10 Sydney NSW 2000 Australia
Phone / Fax61 3 9824 5254 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Imugene does not pay dividends.

Company Executives

As of Aug 2021, following are the company executives and directors listed on Imugene.

NameTitleAgeTotal Pay
Mr. Paul Edward-Alexander HopperExec. Chairman64137.4k
Ms. Leslie ChongCEO, MD & Exec. Director516.03k
Dr. Nicholas J. EdeCTO & COO283.27k
Mr. Phillip Allen HainsCFO & Joint Company Sec.61
Dr. Rita Laeufle M.D., Ph.D.Chief Medical Officer
Dr. Monil Shah M.B.A., Pharm.D.Chief Bus. Officer
Mr. Justyn Peter Stedwell B.Com, B.Com.Joint Company Sec.

Profitability and management effectiveness

Profit margin

-200.70%

Operating margin

-202.66%

Return on assets

-10.74%

Return on equity

-18.40%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Imugene is 1.5B and its enterprise value is 1.34B. The enterprise value to revenue ratio of IMU is 228.66.

The IMU's stocks Beta value is 2.16 making it 116% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Imugene (IMU)

Imugene (ASX:IMU) Frequently Asked Questions

1. What is Imugene's Stock Symbol?

Imugene trades on ASX under the ticker symbol "IMU".

2. What is Imugene's stock price today?

One share of IMU stock can currently be purchased for approximately $0.3.

3. How can I contact Imugene?

Imugene's mailing address is 37 Bligh Street Suite 1006 Level 10 Sydney NSW 2000 Australia. The company can be reached via phone at 61 3 9824 5254.

4. What is Imugene's official website?

The official website of Imugene is http://www.imugene.com.

5. Which share registry manages Imugene's stock?

Imugene's stock is managed by AUTOMIC REGISTRY SERVICES.